Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.50 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.50 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.50 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.50 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.41 |
| ▸ | P2RY2 | P41231 | 4/20 | 0.37 |
| ▸ | P2RY6 | Q15077 | 5/20 | 0.36 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
| ▸ | PYGB | P11216 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6002015 | 1.00 | SLC28A1 (0.50) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL12658269 | 1.00 | SLC28A1 (0.50) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| Hydrogen Sulfide SCHEMBL28043850 | 0.99 | SLC28A1 (0.49) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| Ammonia Solution, Strong SCHEMBL28145131 | 0.99 | SLC28A1 (0.49) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| Phosphoric Acid SCHEMBL18486662 | 0.95 | SLC28A1 (0.46) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| Phosphoric Acid SCHEMBL18486628 | 0.95 | SLC28A1 (0.46) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL13471840 | 0.92 | SLC28A1 (0.48) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| Pyrophosphoric Acid SCHEMBL18486638 | 0.91 | P2RY6 (0.47) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL17479413 | 0.90 | SLC28A1 (0.46) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL15255033 | 0.90 | SLC28A1 (0.46) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1896 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4630049-A1 | IMMUNOGENIC COMPOSITIONS AGAINST INFLUENZA AND RSV | Pfizer Inc. (US) | 2025-10-15 | — | — | EP | claimed |
| CN-120092014-A | RNA constructs and uses thereof | 生物技术欧洲股份公司 | 2025-06-03 | — | — | CN | claimed |
| CN-120064427-A | Method and analysis system for detecting brain nucleic acid hydrolysate spatial distribution based on mass spectrum imaging | 北京脑科学与类脑研究所 | 2025-05-30 | — | — | CN | claimed |
| EP-4558218-A2 | GENOME INSERTIONS IN CELLS | Addition Therapeutics, Inc. (US) | 2025-05-28 | — | — | EP | claimed |
| EP-4549577-A1 | NOVEL INDUCED CYTOPLASMIC IVT (ICIVT)-LIKE COMPOSITION AND THE RELATED VACCINE MEDICINE DESIGNS THEREOF | Mello Biotech Taiwan Co., Ltd. (TW) | 2025-05-07 | — | — | EP | claimed |
| US-20250115932-A1 | INDUCED CYTOPLASMIC IVT (ICIVT)-LIKE COMPOSITION AND THE RELATED VACCINE MEDICINE DESIGNS THEREOF | MELLO BIOTECH TAIWAN CO., LTD. (TW) | 2025-04-10 | — | — | US | claimed |
| CN-119372129-B | 5-Methyluridine producing strain, construction method and application thereof | 天津科技大学 | 2025-03-18 | — | — | CN | claimed |
| EP-4506456-A1 | NOVEL OXO-RNA COMPOSITIONS AND THE RELATED APPLICATIONS THEREOF | Lin, Shi-Lung (US) | 2025-02-12 | — | — | EP | claimed |
| CN-119372129-A | 5-Methyluridine producing strain, construction method and application thereof | 天津科技大学 | 2025-01-28 | — | — | CN | claimed |
| US-20250019709-A1 | NOVEL OXO-RNA COMPOSITIONS AND THE RELATED APPLICATIONS THEREOF | LIN SHI LUNG (US) | 2025-01-16 | — | — | US | claimed |
| WO-2010111494-A1 | SINGLE MOLECULE SENSITIVE PROBES FOR DETECTING RNA | GEORGIA TECH RESEARCH CORPORATION (US) | 2010-09-30 | — | — | WO | claimed |
| CN-101341260-A | Multi-component nucleases and methods of use thereof | JOHNSON & JOHNSON RES PTY LTD (AU) | 2009-01-07 | — | — | CN | claimed |
| EP-0948256-A4 | INDUCTION OF VIRAL MUTATION BY INCORPORATION OF MISCODING RIBONUCLEOSIDE ANALOGS INTO VIRAL RNA | UNIV WASHINGTON (US) | 2007-10-24 | — | — | EP | claimed |
| US-6887707-B2 | Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA | UNIVERSITY OF WASHINGTON (US) | 2005-05-03 | — | — | US | claimed |
| EP-1485395-A2 | NUCLEOTIDE MIMICS AND THEIR PRODRUGS | Biota, Inc. (US) | 2004-12-15 | — | — | EP | claimed |
| WO-2003072757-A9 | NUCLEOTIDE MIMICS AND THEIR PRODRUGS | BIOTA INC (US) | 2004-10-21 | — | — | WO | claimed |
| WO-2003072757-A2 | NUCLEOTIDE MIMICS AND THEIR PRODRUGS | BIOTA, INC. (US) | 2003-09-04 | — | — | WO | claimed |
| US-20030119764-A1 | Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2003-06-26 | — | — | US | claimed |
| EP-0948256-A1 | INDUCTION OF VIRAL MUTATION BY INCORPORATION OF MISCODING RIBONUCLEOSIDE ANALOGS INTO VIRAL RNA | THE UNIVERSITY OF WASHINGTON (US) | 1999-10-13 | — | — | EP | claimed |
| WO-1998018324-A1 | INDUCTION OF VIRAL MUTATION BY INCORPORATION OF MISCODING RIBONUCLEOSIDE ANALOGS INTO VIRAL RNA | THE UNIVERSITY OF WASHINGTON (US) | 1998-05-07 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119764-A1 | Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA | SAMHD1, BCDIN3D, DCTD | SLC28A1 891/4885SLC28A2 952/4885SLC29A1 304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.